JP2024023189A5 - - Google Patents

Download PDF

Info

Publication number
JP2024023189A5
JP2024023189A5 JP2023183500A JP2023183500A JP2024023189A5 JP 2024023189 A5 JP2024023189 A5 JP 2024023189A5 JP 2023183500 A JP2023183500 A JP 2023183500A JP 2023183500 A JP2023183500 A JP 2023183500A JP 2024023189 A5 JP2024023189 A5 JP 2024023189A5
Authority
JP
Japan
Prior art keywords
mutation
cancer
stage
ras
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023183500A
Other languages
English (en)
Japanese (ja)
Other versions
JP7579414B2 (ja
JP2024023189A (ja
Filing date
Publication date
Priority claimed from JP2020542808A external-priority patent/JP6941241B2/ja
Application filed filed Critical
Publication of JP2024023189A publication Critical patent/JP2024023189A/ja
Publication of JP2024023189A5 publication Critical patent/JP2024023189A5/ja
Priority to JP2024187827A priority Critical patent/JP2025026853A/ja
Application granted granted Critical
Publication of JP7579414B2 publication Critical patent/JP7579414B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023183500A 2018-11-09 2023-10-25 縮合環化合物 Active JP7579414B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024187827A JP2025026853A (ja) 2018-11-09 2024-10-25 縮合環化合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/114788 2018-11-09
CN2018114788 2018-11-09
JP2020542808A JP6941241B2 (ja) 2018-11-09 2019-11-08 縮合環化合物
JP2021116809A JP7374960B2 (ja) 2018-11-09 2021-07-15 縮合環化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021116809A Division JP7374960B2 (ja) 2018-11-09 2021-07-15 縮合環化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024187827A Division JP2025026853A (ja) 2018-11-09 2024-10-25 縮合環化合物

Publications (3)

Publication Number Publication Date
JP2024023189A JP2024023189A (ja) 2024-02-21
JP2024023189A5 true JP2024023189A5 (cg-RX-API-DMAC7.html) 2024-05-31
JP7579414B2 JP7579414B2 (ja) 2024-11-07

Family

ID=69232886

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020542808A Active JP6941241B2 (ja) 2018-11-09 2019-11-08 縮合環化合物
JP2021116809A Active JP7374960B2 (ja) 2018-11-09 2021-07-15 縮合環化合物
JP2023183500A Active JP7579414B2 (ja) 2018-11-09 2023-10-25 縮合環化合物
JP2024187827A Pending JP2025026853A (ja) 2018-11-09 2024-10-25 縮合環化合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020542808A Active JP6941241B2 (ja) 2018-11-09 2019-11-08 縮合環化合物
JP2021116809A Active JP7374960B2 (ja) 2018-11-09 2021-07-15 縮合環化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024187827A Pending JP2025026853A (ja) 2018-11-09 2024-10-25 縮合環化合物

Country Status (33)

Country Link
US (3) US11236068B2 (cg-RX-API-DMAC7.html)
EP (2) EP3735299B1 (cg-RX-API-DMAC7.html)
JP (4) JP6941241B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250012188A (cg-RX-API-DMAC7.html)
CN (5) CN112105419B (cg-RX-API-DMAC7.html)
AR (1) AR117194A1 (cg-RX-API-DMAC7.html)
AU (4) AU2019377130B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008986A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087089C (cg-RX-API-DMAC7.html)
CL (2) CL2021001171A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005987A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210229A (cg-RX-API-DMAC7.html)
DK (1) DK3735299T3 (cg-RX-API-DMAC7.html)
ES (1) ES3004042T3 (cg-RX-API-DMAC7.html)
FI (1) FI3735299T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241581T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069365T2 (cg-RX-API-DMAC7.html)
IL (3) IL324078A (cg-RX-API-DMAC7.html)
LT (1) LT3735299T (cg-RX-API-DMAC7.html)
MA (1) MA51530B1 (cg-RX-API-DMAC7.html)
MX (5) MX2021005428A (cg-RX-API-DMAC7.html)
MY (1) MY196726A (cg-RX-API-DMAC7.html)
PE (2) PE20211504A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551065A1 (cg-RX-API-DMAC7.html)
PL (1) PL3735299T3 (cg-RX-API-DMAC7.html)
PT (1) PT3735299T (cg-RX-API-DMAC7.html)
RS (1) RS66280B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103298QA (cg-RX-API-DMAC7.html)
SI (1) SI3735299T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400487T1 (cg-RX-API-DMAC7.html)
TW (3) TWI784209B (cg-RX-API-DMAC7.html)
UA (1) UA127930C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020097537A2 (cg-RX-API-DMAC7.html)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
BR112021023136A2 (pt) 2019-05-21 2022-01-04 Inventisbio Co Ltd Compostos heterocíclicos, métodos de preparação e usos dos mesmos
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
CN114980976A (zh) * 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021120045A1 (en) 2019-12-18 2021-06-24 InventisBio Co., Ltd. Heterocyclic compounds, preparation methods and uses thereof
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
TWI829003B (zh) * 2020-08-12 2024-01-11 美商建南德克公司 喹唑啉化合物之合成
MX2023001997A (es) 2020-08-17 2023-05-12 Betta Pharmaceuticals Co Ltd Compuestos biciclicos, composiciones y usos de los mismos.
CA3191279A1 (en) 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN116323624B (zh) * 2020-09-30 2026-07-10 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
US20240034733A1 (en) * 2020-11-03 2024-02-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4243827A1 (en) * 2020-11-13 2023-09-20 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
KR102975432B1 (ko) * 2020-11-13 2026-06-10 제넨테크, 인크. 고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물
WO2022105855A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
CN116490508A (zh) * 2020-11-20 2023-07-25 北京加科思新药研发有限公司 Kras g12d抑制剂
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
TWI895563B (zh) * 2020-12-08 2025-09-01 美商建南德克公司 用於治療實性瘤之包含krasg12c抑制劑及egfr抑制劑之組成物及方法
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
CN113999226B (zh) * 2020-12-22 2023-01-06 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022135470A1 (zh) * 2020-12-22 2022-06-30 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
CN114685532B (zh) * 2020-12-31 2026-06-16 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
AU2022220678A1 (en) * 2021-02-09 2023-09-21 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2022171013A1 (zh) * 2021-02-09 2022-08-18 南京明德新药研发有限公司 四氢喹唑啉类化合物
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN116867792A (zh) * 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
MX2023008463A (es) * 2021-02-16 2023-12-07 Leidos Biomedical Res Inc Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).
CN117715915A (zh) * 2021-04-09 2024-03-15 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
WO2022221386A1 (en) * 2021-04-14 2022-10-20 Erasca, Inc. Selective kras inhibitors
US20240239788A1 (en) * 2021-04-16 2024-07-18 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12d mutant
WO2022232331A1 (en) * 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
CN117561063A (zh) * 2021-04-29 2024-02-13 安进公司 杂环化合物及使用方法
WO2022235866A1 (en) * 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
AR125921A1 (es) * 2021-05-19 2023-08-23 Genentech Inc Terapia de combinación
US20240300980A1 (en) * 2021-05-22 2024-09-12 Shanghai Kechow Pharma, Inc. Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment
US20240261444A1 (en) * 2021-05-26 2024-08-08 Cornell University Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer
CN115433179A (zh) * 2021-06-03 2022-12-06 正大天晴药业集团股份有限公司 苯并嘧啶类化合物及其医药用途
CA3227138A1 (en) 2021-07-23 2023-01-26 Theras, Inc. Compositions and methods for inhibition of ras
WO2023020518A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. N-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine derivatives and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
US12110276B2 (en) 2021-11-24 2024-10-08 Genentech, Inc. Pyrazolo compounds and methods of use thereof
US12275745B2 (en) 2021-11-24 2025-04-15 Genentech, Inc. Therapeutic compounds and methods of use
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
AU2022421224A1 (en) 2021-12-22 2024-06-20 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
AR128212A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
AR128211A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
CN118742544A (zh) 2022-02-07 2024-10-01 基因泰克公司 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式
AR128449A1 (es) * 2022-02-07 2024-05-08 Genentech Inc Proceso para la síntesis de compuestos de quinazolina
WO2023172737A1 (en) 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CA3244999A1 (en) 2022-03-31 2025-06-13 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
PL4504202T3 (pl) 2022-04-06 2026-05-04 Genentech Inc. Terapie skojarzone do leczenia raka obejmujące GDC-6036 i GDC-0077
CN119365467A (zh) 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
CN115043729B (zh) * 2022-07-04 2024-09-27 青岛大学 一种2,2’-二氟联芳基化合物的不对称合成方法
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
KR20250048078A (ko) 2022-08-11 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 Kras 억제제
JP2025528836A (ja) 2022-08-17 2025-09-02 ツリーライン バイオサイエンシズ インコーポレイテッド ピリドピリミジンKRas阻害剤
US20260137665A1 (en) 2022-10-11 2026-05-21 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
KR20250109197A (ko) 2022-11-21 2025-07-16 트리라인 바이오사이언시스, 인크. 스피로환식 디하이드로피라노피리미딘 KRas 억제제
CN115920658B (zh) * 2023-01-15 2023-10-20 安徽科博瑞环境科技有限公司 低表面能抗污染中空纤维膜及其制备方法
CN120548318A (zh) * 2023-01-18 2025-08-26 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
US20260232666A1 (en) * 2023-01-24 2026-08-13 Theras, Inc. Compositions and methods for inhibition of ras
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20250166103A (ko) 2023-04-06 2025-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료용 약제학적 조성물
CN116396202A (zh) * 2023-04-17 2023-07-07 南京优氟医药科技有限公司 一种(2s,4s)-4-氟代吡咯烷-2-羧酸的制备方法
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
EP4724445A1 (en) 2023-06-06 2026-04-15 Kumquat Biosciences Inc. Substituted heterocycles and uses thereof
US20250000802A1 (en) 2023-06-09 2025-01-02 Hoffmann-La Roche Inc. Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing
EP4735451A1 (en) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025010415A1 (en) * 2023-07-05 2025-01-09 The Regents Of The University Of California Gtpase inhibitors and uses thereof
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
KR20260104082A (ko) 2023-09-29 2026-07-03 디3 바이오 (우씨) 컴퍼니, 리미티드 암의 치료에 사용하기 위한 wx-001 또는 그의 유도체와 kras g12c 억제제의 조합물
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002557A1 (en) 1997-07-11 1999-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V Novel pharmaceutically active compounds interacting with gtp-binding proteins
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
WO2013155223A1 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
MX380928B (es) * 2013-10-10 2025-03-12 Araxes Pharma Llc Inhibidores de kras g12c.
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Rasの阻害剤をスクリーニングするための方法
KR102932353B1 (ko) 2015-11-16 2026-02-27 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2021506862A (ja) 2017-12-19 2021-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Tlr7/8アンタゴニストおよびそれらの使用
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物

Similar Documents

Publication Publication Date Title
US20220387384A1 (en) Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors
JP2025020147A5 (cg-RX-API-DMAC7.html)
JP2022545005A5 (cg-RX-API-DMAC7.html)
EP4337191A1 (en) Egfr inhibitor for the treatment of head and neck cancer
CN101001623B (zh) 抗癌效果增强剂
JP2023506532A5 (cg-RX-API-DMAC7.html)
JP2025511399A5 (cg-RX-API-DMAC7.html)
JP2018526376A5 (cg-RX-API-DMAC7.html)
JP2009538327A5 (cg-RX-API-DMAC7.html)
JP2024527109A5 (cg-RX-API-DMAC7.html)
JP2023513297A5 (cg-RX-API-DMAC7.html)
Lee et al. A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma.
JP2024502446A5 (cg-RX-API-DMAC7.html)
CN110840892A (zh) 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
CN107773556A (zh) 一种具有抗肿瘤药物功效的联合用药物
Nelson et al. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer
Homma et al. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma
EP4489756A1 (en) Methods of treating small cell lung cancer
Isla et al. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study)
TW202120085A (zh) 抗ccr4抗體抵抗性之癌症的治療劑
Wei et al. Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti‐GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma
CN114558023B (zh) 长梗冬青苷在制备抑制肺转移癌的药物中的应用
Liu et al. Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report
Zheng et al. Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906)